title: Cell therapy in bisphosphonate-related osteonecrosis of the jaw.
abstract: OBJECTIVE
  Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a clinical condition found in patients who have received intravenous or oral bisphosphonate therapy for various diseases related to bone. This report describes a novel treatment of BRONJ using autologous bone marrow stem cells, platelet-rich plasma, beta tricalcium phosphate, and demineralized bone matrix.
  
  
  METHODS
  We report a 71-year-old woman with history of multiple myeloma treated with intravenous zoledronic acid during 4 years. After a tooth extraction, the patient presented with a painful BRONJ lesion with no healing wound and cortical bone exposure. The patient was surgically managed with a standardized protocol of autologous stem cell therapy combining bone marrow harvest, cell concentration procedures, and intraoral surgery.
  
  
  RESULTS
  CT scan performed 6 months later showed improvement of bone and concentric ossification. Cellular therapy might be considered a new strategy to heal BRONJ lesions.
authors.affiliation: Cell Therapy Unit, Virgen de la Arrixaca University Hospital, Faculty of Medicine, University of Murcia, Murcia, Spain. margonzalvez@yahoo.com
authors.forename: Mar
authors.initials: M
authors.lastname: Gonzálvez-García
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Rodríguez-Lozano
authors.forename: Victor
authors.initials: V
authors.lastname: Villanueva
authors.forename: Daniel
authors.initials: D
authors.lastname: Segarra-Fenoll
authors.forename: Maria Angeles
authors.initials: MA
authors.lastname: Rodríguez-González
authors.forename: Ricardo
authors.initials: R
authors.lastname: Oñate-Sánchez
authors.forename: Miguel
authors.initials: M
authors.lastname: Blanquer
authors.forename: José María
authors.initials: JM
authors.lastname: Moraleda
mesh_terms: D000368:Aged; D064592:Autografts / Q000637:transplantation*; D001672:Biocompatible Materials / Q000627:therapeutic use; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000601:surgery*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D016026:Bone Marrow Transplantation / Q000379:methods*; D001857:Bone Matrix / Q000637:transplantation; D001861:Bone Regeneration / Q000502:physiology; D018786:Bone Substitutes / Q000627:therapeutic use; D002130:Calcium Phosphates / Q000627:therapeutic use; D003646:Debridement; D004164:Diphosphonates / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007275:Injections, Intravenous; D008336:Mandibular Diseases / Q000601:surgery*; D009101:Multiple Myeloma / Q000188:drug therapy; D053657:Platelet-Rich Plasma / Q000502:physiology; D033581:Stem Cell Transplantation / Q000379:methods*; D000077211:Zoledronic Acid
chemical_list: D001672:Biocompatible Materials; D050071:Bone Density Conservation Agents; D018786:Bone Substitutes; D002130:Calcium Phosphates; D004164:Diphosphonates; D007093:Imidazoles; C485817:beta-tricalcium phosphate; D000077211:Zoledronic Acid